Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,097 questions · 1,119 findings · 70 reviews · Kidney and Transplant

No studies found 271 · 24.2%GRADE not reported 17 · 1.5%Very low 271 · 24.2%Low 349 · 31.2%Moderate 182 · 16.3%High 29 · 2.6%

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Fatal or nonfatal stroke · people with diabetes and kidney disease

Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin receptor blockers showed no clear difference in fatal or nonfatal myocardial infarction Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Cardiovascular mortality · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes cardiovascular death Median compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease

Angiotensin receptor blockers showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease

Angiotensin receptor blockers showed no clear difference in micro‐ to normoalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).

1 finding from 1 review

Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment

Micro‐ to normoalbuminuria6 · people with diabetes and kidney disease

It is very uncertain whether dual therapy (angiotensin‐converting‐enzyme inhibitors plus… changes micro‐ to normoalbuminuria6 compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Death (all causes) · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in all‐cause death Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Doubling of SCr Median · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes doubling of SCr Median compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Cardiovascular mortality · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in cardiovascular death Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Doubling of SCr Median · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in doubling of SCr Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Fatal or nonfatal stroke · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in fatal or nonfatal stroke Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in fatal or nonfatal myocardial infarction Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors (ACEi) alone changes micro‐ to macroalbuminuria Median compared with ACEi plus angiotensin receptor blockers (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in micro‐ to normoalbuminuria Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review